Motley Fool Money cover image

Customers for Life?

Motley Fool Money

00:00

Intro

This chapter examines the effects of the weight loss drugs ZepBound and Munjaro on various industries, with a particular focus on the medtech sector. It highlights ResMed's stock decline related to sleep apnea treatment and discusses the broader implications for markets and investors.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app